{"id":816619,"date":"2025-02-24T08:07:38","date_gmt":"2025-02-24T13:07:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/"},"modified":"2025-02-24T08:07:38","modified_gmt":"2025-02-24T13:07:38","slug":"nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/","title":{"rendered":"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN FRANCISCO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 24, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on <span class=\"xn-chron\">Monday, February 24, 2025<\/span> at <span class=\"xn-chron\">3:00 p.m. EST<\/span> \/ <span class=\"xn-chron\">12:00 p.m. PST<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg\" title=\"(PRNewsfoto\/Nektar Therapeutics)\" alt=\"(PRNewsfoto\/Nektar Therapeutics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Nektar&#8217;s Chief Research &amp; Development Officer, <span class=\"xn-person\">Jonathan Zalevsky<\/span>, Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes\u00a0experts, including:<\/p>\n<ul type=\"disc\">\n<li>Dr. <span class=\"xn-person\">Kevin Herold<\/span>, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at <span class=\"xn-org\">Yale University<\/span> at <span class=\"xn-org\">Yale School of Medicine<\/span>;<\/li>\n<li>Dr. <span class=\"xn-person\">Megan Levings<\/span>, Professor, Department of Surgery and School of Biomedical Engineering at The <span class=\"xn-org\">University Of British Columbia<\/span>; and,<\/li>\n<li>Dr. <span class=\"xn-person\">Daniel Moore<\/span>, Associate Professor of Pediatrics and Pathology, Microbiology &amp; Immunology at <span class=\"xn-org\">Vanderbilt University<\/span> Medical Center.<\/li>\n<\/ul>\n<p>To access the conference call, please pre-register at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4368127-1&amp;h=1268977832&amp;u=https%3A%2F%2Flifescievents.com%2Fevent%2Fnektar%2F&amp;a=Event+Registration\" target=\"_blank\" rel=\"nofollow\">Event Registration<\/a>. The event will also be available for replay through <span class=\"xn-chron\">March 24, 2025<\/span> on Nektar&#8217;s website:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4368127-1&amp;h=2908902618&amp;u=http%3A%2F%2Fwww.nektar.com%2F&amp;a=www.nektar.com\" target=\"_blank\" rel=\"nofollow\">www.nektar.com<\/a>.<\/p>\n<p>\n        <b>About Rezpegaldesleukin<\/b>\n      <\/p>\n<p>Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person&#8217;s body. A failure of the body&#8217;s self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. Rezpegaldesleukin is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. It targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, rezpegaldesleukin may act to bring the immune system back into balance.<\/p>\n<p>Rezpegaldesleukin is wholly-owned by Nektar Therapeutics. It is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. It is currently being evaluated in the REZOLVE-AD study, a randomized, double blind, placebo-controlled Phase <span class=\"xn-money\">2b<\/span> clinical trial for treatment of patients with moderate-to- severe atopic dermatitis (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4368127-1&amp;h=2418448791&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4337715-1%26h%3D1939870519%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fstudy%252FNCT06136741%253Fintr%253DREZOLVE-AD%2526rank%253D1%26a%3DNCT06136741&amp;a=NCT06136741\" target=\"_blank\" rel=\"nofollow\">NCT06136741<\/a>). In addition to the REZOLVE-AD study, it is also being evaluated in the REZOLVE-AA study, a randomized, double blind, placebo-controlled Phase <span class=\"xn-money\">2b<\/span> clinical trial for treatment of patients with severe-to-very-severe alopecia areata (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4368127-1&amp;h=528994416&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4337715-1%26h%3D3670014230%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fstudy%252FNCT06340360%253Fintr%253DREZOLVE-AA%2526rank%253D1%26a%3DNCT06340360&amp;a=NCT06340360\" target=\"_blank\" rel=\"nofollow\">NCT06340360<\/a>).<\/p>\n<p>The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.<\/p>\n<p>\n        <b>About Nektar Therapeutics<\/b>\n      <\/p>\n<p>Nektar Therapeutics\u00a0is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar&#8217;s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase <span class=\"xn-money\">2b<\/span> clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar&#8217;s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system&#8217;s natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in\u00a0San Francisco, <span class=\"xn-location\">California<\/span>. For further information, visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4368127-1&amp;h=2908902618&amp;u=http%3A%2F%2Fwww.nektar.com%2F&amp;a=www.nektar.com\" target=\"_blank\" rel=\"nofollow\">www.nektar.com<\/a>\u00a0and follow Nektar on LinkedIn.<\/p>\n<p>\n        <b>Cautionary Note Regarding Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements which can be identified by words such as: &#8220;will,&#8221; &#8220;announce,&#8221; &#8220;potential,&#8221; &#8220;advance,&#8221; &#8220;anticipate,&#8221; &#8220;can,&#8221; and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the therapeutic potential of, and future development plans for, rezpegaldesleukin. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin is an investigational agent and continued research and development for this drug candidate is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin is in clinical development, and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (v) a Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in\u00a0the <span class=\"xn-location\">United States<\/span>; (vi) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vi) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the\u00a0Securities and Exchange Commission\u00a0on\u00a0November 8, 2024. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p>\n        <b>Contact<\/b>:<\/p>\n<p>\n        <b>For Investors:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Vivian Wu<\/span> of Nektar Therapeutics<br \/>628-895-0661<\/p>\n<p>\n        <b>For Media:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Madelin Hawtin<\/span><br \/>\n        <br \/>LifeSci\u00a0Communications<br \/>603-714-2638<br \/><a href=\"mailto:mhawtin@lifescicomms.com\" target=\"_blank\" rel=\"nofollow\">mhawtin@lifescicomms.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF25102&amp;sd=2025-02-24\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/nektar-therapeutics-to-host-virtual-investor--analyst-event-with-type-1-diabetes-experts-on-february-24th-302383306.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/nektar-therapeutics-to-host-virtual-investor&#8211;analyst-event-with-type-1-diabetes-experts-on-february-24th-302383306.html<\/a><\/p>\n<p>SOURCE  Nektar Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF25102&amp;Transmission_Id=202502240700PR_NEWS_USPR_____SF25102&amp;DateId=20250224\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN FRANCISCO , Feb. 24, 2025 \/PRNewswire\/ &#8212;\u00a0Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST \/ 12:00 p.m. PST. Nektar&#8217;s Chief Research &amp; Development Officer, Jonathan Zalevsky, Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes\u00a0experts, including: Dr. Kevin Herold, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine; Dr. Megan Levings, Professor, Department of Surgery and School of Biomedical Engineering at The University Of British Columbia; and, Dr. Daniel Moore, Associate Professor of Pediatrics and Pathology, Microbiology &amp; Immunology at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816619","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN FRANCISCO , Feb. 24, 2025 \/PRNewswire\/ &#8212;\u00a0Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST \/ 12:00 p.m. PST. Nektar&#8217;s Chief Research &amp; Development Officer, Jonathan Zalevsky, Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes\u00a0experts, including: Dr. Kevin Herold, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine; Dr. Megan Levings, Professor, Department of Surgery and School of Biomedical Engineering at The University Of British Columbia; and, Dr. Daniel Moore, Associate Professor of Pediatrics and Pathology, Microbiology &amp; Immunology at &hellip; Continue reading &quot;Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T13:07:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th\",\"datePublished\":\"2025-02-24T13:07:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/\"},\"wordCount\":1041,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/nektar_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/\",\"name\":\"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/nektar_logo.jpg\",\"datePublished\":\"2025-02-24T13:07:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/nektar_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/nektar_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/","og_locale":"en_US","og_type":"article","og_title":"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th - Market Newsdesk","og_description":"PR Newswire SAN FRANCISCO , Feb. 24, 2025 \/PRNewswire\/ &#8212;\u00a0Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST \/ 12:00 p.m. PST. Nektar&#8217;s Chief Research &amp; Development Officer, Jonathan Zalevsky, Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes\u00a0experts, including: Dr. Kevin Herold, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine; Dr. Megan Levings, Professor, Department of Surgery and School of Biomedical Engineering at The University Of British Columbia; and, Dr. Daniel Moore, Associate Professor of Pediatrics and Pathology, Microbiology &amp; Immunology at &hellip; Continue reading \"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T13:07:38+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th","datePublished":"2025-02-24T13:07:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/"},"wordCount":1041,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/","name":"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg","datePublished":"2025-02-24T13:07:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-february-24th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nektar Therapeutics to Host Virtual Investor &amp; Analyst Event with Type 1 Diabetes Experts on February 24th"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816619"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}